Covadonga Álvarez-Álvarez

Dr. Covadonga Álvarez-Álvarez

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2025 in Colloids and Interfaces
Verified
Journal Article
Open access
PDF file
ZDZaid Dahma
Zaid Dahma
Covadonga Álvarez-ÁlvarezCovadonga Álvarez-Álvarez
Covadonga Álvarez-Álvarez
Paloma Marina de la Torre-IglesiasPaloma Marina de la Torre-Iglesias
Paloma Marina de la Torre-Iglesias
The solubility behavior of drugs is a critical factor in formulation development. Approximately 40–45% of new drugs face market entry challenges due to low water solubility. Enhancing drug bioavailability is thus essential in developing pharmaceutical dosage forms. Many biopharmaceutical class II and IV drugs are commonly prescribed to treat inflammations, infections, and pain from various pathologies. Their oral administration has several drawbacks, including significant first-pass liver effects, low bioavailability, and adverse gastrointestinal effects. Topical application has gained relevance due to its advantages in delivering drugs directly to the target site, avoiding gastrointestinal irritation, and increasing their effectiveness. However, topical hydrogel formulations with poorly water-soluble drugs face challenges related to the skin’s permeability. Therefore, preparing topical hydrogels using solid dispersions (SDs) is an effective strategy to enhance the dissolution rate of poorly soluble drugs, thereby improving their topical bioavailability. In this review, the concepts of SDs, topical delivery systems, and topical hydrogel formulations incorporating SDs, as well as their preparation methods, characterization, and applications, will be discussed.

11 May 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MPMercedes Prieto-Escolar
Mercedes Prieto-Escolar
JTJuan J. Torrado
Juan J. Torrado
Covadonga Álvarez-ÁlvarezCovadonga Álvarez-Álvarez
Covadonga Álvarez-Álvarez
ARAlejandro Ruiz-Picazo
Alejandro Ruiz-Picazo
MSMarta Simón-Vázquez
Marta Simón-Vázquez
Marival BermejoMarival Bermejo
Marival Bermejo
Montelukast is a weak acid drug characterized by its low solubility in the range of pH 1.2 to 4.5, which may lead to dissolution-limited absorption. The aim of this paper is to develop an in vivo predictive dissolution method for montelukast and to check its performance by establishing a level-A in vitro-in vivo correlation (IVIVC). During the development of a generic film-coated tablet formulation, two clinical trials were done with three different experimental formulations to achieve a similar formulation to the reference one. A dissolution test procedure with a flow-through cell (USP IV) was used to predict the in vivo absorption behavior. The method proposed is based on a flow rate of 5 mL/min and changes of pH mediums from 1.2 to 4.5 and then to 6.8 with standard pharmacopoeia buffers. In order to improve the dissolution of montelukast, sodium dodecyl sulfate was added to the 4.5 and 6.8 pH mediums. Dissolution profiles in from the new method were used to develop a level-A IVIVC. One-step level-A IVIVC was developed from dissolution profiles and fractions absorbed obtained by the Loo–Riegelman method. Time scaling with Levy’s plot was necessary to achieve a linear IVIVC. One-step differential equation-based IVIVC was also developed with a time-scaling function. The developed method showed similar results to a previously proposed biopredictive method for montelukast, and the added value showed the ability to discriminate among different release rates in vitro, matching the in vivo clinical bioequivalence results.

20 July 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ENEva Navarro-Ruíz
Eva Navarro-Ruíz
Covadonga Álvarez-ÁlvarezCovadonga Álvarez-Álvarez
Covadonga Álvarez-Álvarez
Mª Ángeles Peña FernándezMª Ángeles Peña Fernández
Mª Ángeles Peña Fernández
CSCarlos Torrado Salmerón
Carlos Torrado Salmerón
ZDZaid Dahma
Zaid Dahma
Paloma Marina de la Torre-IglesiasPaloma Marina de la Torre-Iglesias
Paloma Marina de la Torre-Iglesias
The aim of this research is the development of new colonic release systems of meloxicam (MLX) a non-steroidal anti-inflammatory drug (NSAIDs) with pH and time-dependent vehicles for cancer or autoimmune diseases. The colon has a higher pH than the rest of the gastrointestinal tract (GIT) and this can be used as a modified release strategy. Eudragit® polymers are the most widely used synthetic products in the design of colonic release formulations because they might offer mucoadhesiveness and pH-dependent release. Colonic delivery systems produced with pH-dependent and permeable polymers (FS-30D) or with pH-independent and low permeability polymers (NM-30D), must dissolve at a pH range of 6.0–7.0 to delay the release of the drug and prevent degradation in the GIT, before reaching the colon. The conditions prepared to simulate a gastrointestinal transit showed the CNM multiparticulate system, composed of Eudragit® NM and cellulose, as the best release option for MLX with a more sustained release with respect to the other formulations. CNM formulation followed Higuchi and First-order release kinetics, thus MLX release was controlled by a combination of diffusion and polymers swelling/eroding processes.

30 July 2024 in Polymers
Verified
Journal Article
Open access
PDF file
ZDZaid Dahma
Zaid Dahma
AIAlexandra Ibáñez-Escribano
Alexandra Ibáñez-Escribano
CFCristina Fonseca-Berzal
Cristina Fonseca-Berzal
JGJuan José García-Rodríguez
Juan José García-Rodríguez
Covadonga Álvarez-ÁlvarezCovadonga Álvarez-Álvarez
Covadonga Álvarez-Álvarez
Paloma Marina de la Torre-IglesiasPaloma Marina de la Torre-Iglesias
Paloma Marina de la Torre-Iglesias
Indomethacin (IND) as a non-selective cyclooxygenase 1 and 2 inhibitor administered orally causes numerous adverse effects, mostly related to the gastrointestinal tract. Moreover, when applied exogenously in topical preparations, there are obstacles to its permeation through the stratum corneum due to its low water solubility and susceptibility to photodegradation. In this work, solid dispersions (SDs) of IND with low-substituted hydroxypropyl cellulose (LHPC) were developed. The IND—SDs were incorporated into a hydroxypropyl guar (HPG) hydrogel to enhance drug solubility on the skin. The hydrogels were characterized by scanning electron microscopy (SEM), differential scanning calorimetry (DSC), powder X-ray diffraction (XRPD), Fourier-transform infrared spectroscopy (FTIR), viscosity, drug release, and unspecific cytotoxicity in mammalian cells. SEM showed a highly porous structure for SD hydrogels. DSC and XRPD studies showed that amorphous IND species were formed; therefore, these hydrogels exhibited superior drug release in comparison with IND raw material hydrogels. FTIR evidenced the presence of the hydrogen bond in the SD hydrogel. The rheology parameter viscosity increased across gels formulated with SDs in comparison with hydrogels with pure IND. In addition, IND—SD hydrogels combine the advantages of a suitable viscosity for dermal use and no potentially hazardous skin irritation. This study suggests that the formulated IND—SD hydrogels represent a suitable candidate for topical administration.

18 March 2024 in Gels
Verified
Journal Article
Open access
PDF file
ZDZaid Dahma
Zaid Dahma
CSCarlos Torrado Salmerón
Carlos Torrado Salmerón
Covadonga Álvarez-ÁlvarezCovadonga Álvarez-Álvarez
Covadonga Álvarez-Álvarez
VGVíctor Guarnizo-Herrero
Víctor Guarnizo-Herrero
BABorja Martínez Alonso
Borja Martínez Alonso
Paloma Marina de la Torre-IglesiasPaloma Marina de la Torre-Iglesias
Paloma Marina de la Torre-Iglesias
Meloxicam (MX) is a poorly water-soluble drug with severe gastrointestinal side effects. Topical hydrogel of hydroxypropyl guar (HPG) was formulated using a solid dispersion (SD) of MX with hydroxypropyl cellulose (LHPC) as an alternative to oral administration. The development of a solid dispersion with an adequate MX:LHPC ratio could increase the topical delivery of meloxicam. Solid dispersions showed high MX solubility values and were related to an increase in hydrophilicity. The drug/polymer and polymer/polymer interactions of solid dispersions within the HPG hydrogels were evaluated by SEM, DSC, FTIR, and viscosity studies. A porous structure was observed in the solid dispersion hydrogel MX:LHPC (1:2.5) and its higher viscosity was related to a high increase in hydrogen bonds among the –OH groups from LHPC and HPG with water molecules. In vitro drug release studies showed increases of 3.20 and 3.97-fold for hydrogels with MX:LHPC ratios of (1:1) and (1:2.5), respectively, at 2 h compared to hydrogel with pure MX. Finally, a fitting transition from zero to first-order model was observed for these hydrogels containing solid dispersions, while the n value of Korsmeyer–Peppas model indicated that release mechanism is governed by diffusion through an important relaxation of the polymer.

5 June 2026 in Next Research
Verified
Journal Article
Open access
SPSacha G. Pozo-Puertas
Sacha G. Pozo-Puertas
Paloma Marina de la Torre-IglesiasPaloma Marina de la Torre-Iglesias
Paloma Marina de la Torre-Iglesias
RPRosa Palomeque-Cabañas
Rosa Palomeque-Cabañas
ZDZaid Dahma
Zaid Dahma
Covadonga Álvarez-ÁlvarezCovadonga Álvarez-Álvarez
Covadonga Álvarez-Álvarez